Current Therapeutic Strategies and Future Perspectives for the Treatment of Venous Thromboembolism

David      A. Garcia

doi:10.2174/138161210793563347

Abstract

Pulmonary embolism (PE) and deep vein thrombosis (DVT) are widely regarded as manifestations of a single disease, venous thromboembolism (VTE). An evidence-based approach to the treatment of acute VTE will be reviewed here. Currently available therapeutic options will be emphasized; possible future treatment approaches will be discussed briefly. The chronic management of VTE involves assessment of the risks and benefits of prolonged anticoagulation and is discussed in more detail elsewhere in this issue.

Keywords: Venous thromboembolism, anticoagulation, thrombolysis, Pulmonary embolism, deep vein thrombosis, vitamin K antagonists, rapid-acting gly-cosaminoglycan agent, fondaparinux, low molecular weight heparin, thrombolytic therapy, activated partial throm-boplastin time, idiopathic VTE, Systemic Thrombolysis, Pulmonary Embolectomy, Dalteparin, Enoxaparin, Tinzaparin, Inferior Vena Cava Interruption, craniotomy, caval thrombosis, DVT, tPA-induced bleeding, thrombotic syndrome, Statins, HmGCoA Reductase inhibitors, C-reactive protein, Aspirin, arterial thrombotic events, myocardial infarction, VKA-based anticoagulation, warfarin